


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (Currently amended): A compound of the formula



in which

R<sub>1</sub> is CH(R<sub>e</sub>)C(=O)N(R<sub>a</sub>)R<sub>b</sub> or (CH<sub>2</sub>)<sub>k</sub>N(R<sub>c</sub>)R<sub>d</sub>, wherein

k is 0, 1 or 2;

R<sub>a</sub> and R<sub>b</sub>, independently, are hydrogen or an optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl or heteroaryl(C<sub>1-4</sub>)alkyl group,

R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen or an optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl, chroman-4-yl, isochroman-4-yl, thiochroman-4-yl, isothiochroman-4-yl, 1,1-dioxo-1λ\*6\*-thiochroman-4-yl, 2,2-dioxo-2λ\*6\*-isothiochroman-4-yl, 1,2,3,4-tetrahydro-quinolin-4-yl, 1,2,3,4-tetrahydro-isoquinolin-4-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1,1-dioxo-1,2,3,4-tetrahydro-1λ\*6\*-benzo[e][1,2]thiazin-4-yl, 2,2-dioxo-1,2,3,4-tetrahydro-2λ\*6\*-benzo[c][1,2]thiazin-4-yl, 1,1-dioxo-3,4-dihydro-1H-1λ\*6\*-benzo[c][1,2]oxathiin-4-yl, 2,2-dioxo-3,4-dihydro-2H-2λ\*6\*-benzo[e][1,2]oxathiin-4-yl, 2,3,4,5-tetrahydro-benzo[b]oxepin-5-yl or 1,3,4,5-tetrahydro-benzo[c]oxepin-5-yl group, or

R<sub>a</sub> and R<sub>b</sub>, or R<sub>c</sub> and R<sub>d</sub>, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, 1-piperidinyl, 4-morpholinyl or piperazinyl group; and

$R_e$  is optionally substituted ( $C_{1-8}$ )alkyl, ( $C_{1-4}$ )alkoxy( $C_{1-4}$ )alkyl, ( $C_{3-7}$ )cycloalkyl or ( $C_{3-7}$ )cycloalkyl( $C_{1-4}$ )alkyl;

$R_2$  is hydrogen or ( $C_{1-4}$ )alkyl;

$R_3$  is hydrogen, ( $C_{1-6}$ )alkyl or an optionally substituted ( $C_{1-6}$ )alkylOC(=O)NH, ( $C_{3-7}$ )cycloalkylOC(=O)NH, ( $C_{3-7}$ )cycloalkyl( $C_{1-4}$ )alkylOC(=O)NH, aryl( $C_{1-4}$ )alkylOC(=O)NH, heteroaryl( $C_{1-4}$ )alkylOC(=O)NH, ( $C_{1-4}$ )alkylC(=O)NH, ( $C_{3-7}$ )cycloalkylC(=O)NH, arylC(=O)NH, aryl( $C_{1-4}$ )alkylC(=O)NH, heteroarylC(=O)NH or heteroaryl( $C_{1-4}$ )alkylC(=O)NH group;

$U$  is a bond,  $-CF_2-$ ,  $-CF_2CF_2-$ ,  $-CHF-$ ,  $-CHFCHF-$ , cycloprop-1,2-ylene, ( $C_{1-3}$ )alkylenoxy, ( $C_{1-8}$ )alkylene,  $NR_g$  or an aromatic or heteroaromatic ring, which ring is optionally substituted with halogen, ( $C_{1-4}$ )alkoxy, hydroxy or ( $C_{1-4}$ )alkyl, whereby  $Z$  and  $V$  are in ortho- or meta-position to each other, wherein

$R_g$  is hydrogen, ( $C_{1-8}$ )alkyl or ( $C_{3-7}$ )cycloalkyl;

$V$  is  $CH=CH$ , cycloprop-1,2-ylene,  $CH_2CH(OH)$ ,  $CH(OH)CH_2$  or  $CR_hR_hCR_hR_h$ , wherein each  $R_h$ , independently, is hydrogen, fluorine or ( $C_{1-4}$ )alkyl;

$W$  is ( $C_{1-6}$ )alkylene,  $-O-$ ,  $-S-$ ,  $S(=O)_2-$ ,  $C(=O)-$ ,  $C(=O)O-$ ,  $OC(=O)-$ ,  $N(R_f)C(=O)-$ ,  $C(=O)NR_f$  or  $NR_f$ , wherein

$R_f$  is hydrogen or ( $C_{1-4}$ )alkyl;

$X$  is an optionally substituted ( $C_{1-4}$ )alkanylylidene [I,] or ( $C_{1-4}$ )alkylene, ( $C_{3-7}$ )cycloalkylene, piperidin-diyl, pyrrolidin-diyl, benzothiazole-4,6-diyl, benzoxazole-4,6-diyl, 1H-benzotriazole-4,6-diyl, imidazo[1,2-a]pyridine-6,8-diyl, benzo[1,2,5]oxadiazole-4,6-diyl, benzo[1,2,5]thiadiazole-4,6-diyl, 1H-indole-5,7-diyl, 1H-indole-4,6-diyl, 1H-benzimidazole-4,6-diyl or 1H-indazole-1,6-diyl group or an optionally substituted aromatic or heteroaromatic ring, whereby  $Y$  and  $C(=O)NR_2$  are in meta-position to each other;

$Y$  is a bond,  $O$ ,  $S(=O)_2$ ,  $S(=O)_2NR_g$ ,  $N(R_g)S(=O)_2$ ,  $NR_g$ ,  $C(R_g)OH$ ,  $C(=O)NR_g$  [I,] or  $N(R_g)C(=O)$ ,  $C(=O)N(R_g)O$  or  $ON(R_g)C(=O)$ , wherein


R<sub>g</sub> is hydrogen, (C<sub>1-8</sub>)alkyl or (C<sub>3-7</sub>)cycloalkyl;

Z is O, CH<sub>2</sub>, CF<sub>2</sub>, CHF, cycloprop-1,2-ylene or a bond; and

n is 0 to 5,

the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form.

Claim 2. (Original): A process for the preparation of a compound as defined in claim 1 of the formula I, in free base form or in acid addition salt form, comprising the steps of cyclisation by metathesis of a compound of the formula



in which R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, U, W, X, Y, Z and n are as defined for the formula I, in the presence of a catalyst, for instance a ruthenium, tungsten or molybdenum complex, optionally followed by reduction, oxidation or functionalisation of the resulting carbon-carbon-double bond, and of recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.

Claim 3. (Canceled)

Claim 4. (Canceled)

Claim 5. (Original): A pharmaceutical composition comprising a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, as active ingredient and a pharmaceutical carrier or diluent.

Claim 6-9. (Canceled)